WE Life Sciences’ Post

🦠 Making progress in complex diseases such as Crohn's   🧪 This is what our participating company BiOkuris - also a sister company of KiOmed Pharma and KitoZyme - is successfully doing.   ✅  The drug BK003 is entering a clinical trial phase, the results of which are expected to improve the quality of life of patients suffering from Crohn's disease and irritable bowel syndrome (IBS)-type symptoms. The innovative product developed is a nutritional formulation comprising chitin glucan and an amalgam of essential vitamins and minerals. It seems clear that factors such as genetics, environment and immune system dysfunction play an important role.   🚀  This is the second clinical study conducted by Biokuris. The first involved a similar product, but targeted irritable bowel syndrome more strictly.   🔬 It's interesting to be working with Life Sciences companies like Biokuris, which are exploring other treatment, including medical nutrition.   Well done to the teams for their determination in tackling complex health problems that remain unexplained to this day! Read the article in le d'écho. The link is bolow in the comments part. #lifesciences #medecine #nutritionmedicale Gery Lefebvre François Blondel

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics